Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands

Regulatory Toxicology and Pharmacology

Volumn 63, Issue 1, 2012, Pages 55-63

  van Amsterdam, Jan G C ^a   van Laar, Margriet ^b   Brunt, Tibor M ^b   van den Brink, Wim ^c,d  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

Author keywords

Anesthetic; GBL; GHB; Illicit drugs; Neurotoxicity; Risk assessment

Indexed keywords

4 HYDROXYBUTYRIC ACID; OXYBATE SODIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; BRADYCARDIA; CHEYNE STOKES BREATHING; COMA; COMATOSE PATIENT; CONVULSION; CRIMINAL BEHAVIOR; DRUG FATALITY; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EVALUATION RESEARCH; HEALTH SERVICE; HUMAN; INSOMNIA; LEGAL LIABILITY; LETHAL DOSE; MAJOR CLINICAL STUDY; MORTALITY; NARCOLEPSY; NAUSEA AND VOMITING; NETHERLANDS; NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RESPIRATION DEPRESSION; RISK ASSESSMENT; SUBSTANCE ABUSE; TOXICOKINETICS; TREATMENT INDICATION; UNCONSCIOUSNESS;

HUMANS; HYDROXYBUTYRATES; LEGISLATION, DRUG; NETHERLANDS; RISK ASSESSMENT; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 84859043733     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.03.005     Document Type: Article

References (105)

1. Aarts M., van Melick D., Parlar D., van de Velde L. Onderzoeksrapport: GHB-gebruik in Noord-Limburg 2010, GGZ Noord-en Midden-Limburg, Venray.
2. GBL & 1,4-BD: Assessment of Risk to the Individual and Communities in the UK 2007, ACMD, Advisory Council on the Misuse of Drugs (ACMD).
3. Addolorato G., Caputo F., Capristo E., Stefanini G.F., Gasbarrini G. Gamma-hydroxybutyric acid: efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol 2002, 20:217-222.
4. Amato L., Minozzi S., Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst. Rev. 2011, 15:CD008537.
5. Arena C., Fung H.L. Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J. Pharm. Sci. 1980, 69:356-358.
6. Barker J.C., Harris S.L., Dyer J.E. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J. Psychoactive Drugs 2007, 39:115-129.
7. Beltman W., van Riel A.J.P.H., Wijnands-Kleukers A.P.G., Vriesman M.F., van den Hengel-Koot I.S., De Vries I., Meulenbelt J. Smartshops. Overzicht van producten, geclaimde werking en hun medisch-toxicologische relevantie. RIVM rapport 1999, 348802017:128-131.
8. CAM, 2008. Coördinatiepunt Assessment en Monitoring nieuwe drugs (CAM). Risicoschatting cannabis 2008. http://www.rivm.nl/bibliotheek/digitaaldepot/CAM_risicoschattingsrapport_cannabis_2008.pdf.
9. Carter L.P., Griffiths R.R., Mintzer M.Z. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacol. (Berl) 2009, 206:141-154.
10. Carter L.P., Pardi D., Gorsline J., Griffiths R.R. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009, 104:1-10.
11. Chin R.L., Sporer K.A., Cullison B., Dyer J.E., Wu T.D. Clinical course of gamma-hydroxybutyrate overdose. Ann. Emerg. Med. 1998, 31:716-722.
12. Dart R.C. Medical Toxicology 2004, Lippincott Williams & Wilkins, Baltimore/London, (pp. 1096-1102). third ed.
13. de Jong M., Poelmans I., Linck H., Ernst M. Tendens 2008: alcohol-en drugsgebruik bij jongeren en jongvolwassenen in Gelderland 2008, IrisZorg, Arnhem.
14. Degenhardt L., Darke S., Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002, 67:89-94.
15. Degenhardt L., Darke Sh., Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 2003, 98:199-204.
16. Degenhardt L., Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int. J. Drug Policy 2008, 19:311-316.
17. Degenhardt L., Hall W.D., Lynskey M., McGrath J., McLaren J., Calabria B., Whiteford H., Vos T. Should burden of disease estimates include cannabis use as a risk factor for psychosis?. PLoS. Med. 2009, 6:e1000133.
18. Dietze P.M., Cvetkovski S., Barratt M.J., Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne. Victoria Med. J. Aust. 2008, 188:709-711.
19. Dillon, P., 2009. As cited in Sydney Morning Herald. http://www.smh.com.au.
20. Dunn M., Topp L., Degenhardt L. GHB in Sydney, Australia, 2000-2006: a case study of the EDRS as a strategic early warning system. Int. J. Drug Policy 2009, 20:413-417.
21. EDND, 2011. European Information Centre and Database on New Drugs. EMCDDA Early Warning System about GHB.
22. EMCDDA, 2000. European Monitoring Centre for Drugs and Drug Addiction. Report on the Risk Assessment of GHB in the Framework of the Joint Action on New Synthetic Drugs, Lisbon.
23. EMCDDA, 2011. European Information Centre and Database on New Drugs. EMCDDA Early Warning System about GHB.
24. Freese T.E., Miotto K., Reback C.J. The effects and consequences of selected club drugs. J. Subst. Abuse Treat. 2002, 23:151-156.
25. Friedman J., Westlake R., Furman M. "Grievous bodily harm:" gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996, 46:469-471.
26. Galloway G.P., Frederick-Osborne S.L., Seymour R., Contini S.E., Smith D.E. Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 2000, 20:263-269.
27. Gónzalez A., Nutt D.J. Gamma hydroxy butyrate abuse and dependency. J. Psychopharmacol. 2005, 19:195-204.
28. Hodges B., Everett J. Acute toxicity from home-brewed gamma-hydroxybutyrate. J.A.B.F.P. 1998, 11:154-157.
29. Hornfeld C.S., Lothridge K., Upshaw Downs J.C. Forensic science update: gamma-hydroxybutyrate (GHB). Forensic Sci. Commun. 2002, 4:1.
30. Hurlbut K.M., Silverstein S. Gamma butyric acid and related compounds. In: Hurlbut, K.M., Silverstein, S., (Eds). Poisindex. POISINDEX® System 2000, MICROMEDEX, Inc., Greenwood Village, Colorado, (Edition expires 6/2000).
31. Irwin R.D. NTP Summary Report on the Metabolism, Disposition, and Toxicity of 1,4-Butanediol. NIH Publication No. 96-3932 1996, United States Department of Health and Human Services, Public Health Service, National Institute of Health.
32. Jones A.W., Holmgren A., Kugelberg F.C. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Sci. Med. Pathol. 2008, 4:205-211.
33. Kamal R. Afkicken van GHB: levensgevaarlijk. Ned. Tijdschr. Geneeskd. 2010, 154:A1286.
34. Kepper A., Veen V., Monshouwer K., Stevens G., Drost W., de Voorne T., Vollebergh W. Middelengebruik bij jongens in Justitiële Jeugdinrichtingen. Het gebruik van tabak, alcohol, cannabis en harddrugs bij jongens met en zonder PIJ-maatregel 2009, Universiteit Utrecht, Utrecht.
35. Kerrigan S. In vitro production of gamma-hydroxybutyrate in antemortem urine samples. J. Anal. Toxicol. 2002, 26:571-574.
36. Keshavarz R., Merchant R.C. Emergency contraception: a survey of emergency department practitioners. Acad. Emerg. Med. 2002, 9:69-74.
37. Klein M., Kramer F. Rave drugs: pharmacological considerations. Am. Ass. Nurse Anesth. J 2004, 72:61-67.
38. Knudsen K., Greter J., Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin. Toxicol. (Phila) 2008, 46:187-192.
39. Knudsen K., Jonsson U., Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol. Scand. 2010, 54:987-992.
40. Koesters S.C., Rogers P.D., Rajasingham C.R. MDMA ('ecstasy') and other 'club drugs'. The new epidemic. Pediatr. Clin. North Am. 2002, 49:415-433.
41. Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie (KNMP), 2006. Informatorium medicamentorum. Den Haag, The Netherlands.
42. Korf, D.J., and Nabben, T., 2011. GHB: Trends, and characteristics and user profiles. Report to CAM.
43. Korf D.J., Nabben T., Leenders F., Benschop A. GHB: Tussen Extase en Narcose 2002, Rozenberg Publishers, Amsterdam.
44. Krul J., Blankers M., Girbes A.R.J. Substance-related health problems during rave parties in the Netherlands (1997-2008). PLoS ONE 2011, 6:e29620.
45. Krul J., Girbes A.R.J. Gamma-hydroxybutyrate: Experience of 9years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin. Toxicol. 2011, 49:311-315.
46. Kugelberg F.C., Holmgren A., Eklund A., Jones A.W. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int. J. Legal Med. 2010, 124:1-6.
47. Laborit H. Sodium 4-hydroxybutyrate. Int. J. Neuropharmacol. 1964, 3:433-451.
48. LeBeau M.A., Monygomery M.A., Morris-Kukoski C., Schaff J.E., Deakin A. Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples. Forensic Sci. Intern. 2007, 169:152-156.
49. Lenz D., Rothschild M., Kroener L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gammahydroxybutyric acid and gamma-butyrolactone. Ther. Drug Monit. 2008, 30:755-761.
50. Li J., Stokes S.A., Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann. Emerg. Med. 1998, 31:729-736.
51. Lora-Tamayo C., Tena T., Rodríguez A., Sancho J.R., Molina E. Intoxication due to 1,4-butanediol. Forensic Sci. Int. 2003, 133:256-259.
52. Maitre M., Hechler V., Vayer P., Gobaille S., Cash C.D., Schmitt M., Bourguignon J.J. A specific GHB receptor ligand possess both antagonistic and anticonvulsant properties. J. Pharmacol. Exp. Ther. 1990, 255:657-663.
53. Mamelak M., Scharf M.B., Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings. Sleep 1986, 9:285-289.
54. McDonough M., Kennedy N., Glasper A., Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004, 75:3-9.
55. McDowell D.M. MDMA, ketamine, GHB, and the "club drug" scene. Textbook of Substance Abuse Treatment 2004, 321-331. American Psychiatric Publishing, Arlington, VA. M. Galanter, H.D. Kleber (Eds.).
56. Miotto K., Darakjian J., Basch J., Murray S., Zogg J., Rawson R. Gamma-hydroxybutyric acid: Patterns of use, effects and withdrawal. Am. J. Addict. 2001, 10:232-241.
57. Miró O., Nogué S., Espinosa G., To-Figueras J., Sanchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J. Toxicol. Clin. Toxicol. 2002, 40:129-135.
58. Moller J.T., Cluitmans P., Rasmussen L.S., Houx P., Rasmussen H., Canet J., Rabbitt P., Jolles J., Larsen K., Hanning C.D., Langeron O., Johnson T., Lauven P.M., Kristensen P.A., Biedler A., van B.H., Fraidakis O., Silverstein J.H., Beneken J.E., Gravenstein J.S. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 1998, 351:857-861.
59. Nabben T., Benschop A., Korf D.J. Antenne 2006: Trends in Alcohol, tabak en drugs bij jonge Amsterdammers 2007, Rozenberg Publishers, Amsterdam.
60. Nabben T., Benschop A., Korf D.J. Antenne 2009: Trends in Alcohol, tabak en drugs bij jonge Amsterdammers 2010, Rozenberg Publishers, Amsterdam.
61. Németh Z., Kun B., Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J. Psychopharmacol. 2010, 24:1281-1287.
62. NHS, 2009. South London and Maudsley NHS Trust Oral Presentation on GHB/GBL, December 2009.
63. NIH, 1992. Toxicology and carcinogenesis studies of ã-butyrolactone in F344/N rats and B6C3F1 mice. US Dept. Health and Human Services, NIH, Technical report series No. 406.
64. Novadic-Kentron, 2011. Onrustbarende stijging van GHB-verslaafden zet door. Jaarbericht Novadic-Kentron.
65. Office of National Drug Control Policy, 1998. Gamma hydroxybutyrate (GHB). http://www.ncjrs.gov/pdffiles/172867.pdf.
66. Ouwehand, A.W., Wisselink, D.J.K.W.G., van Delden, E.B., Mol, A., 2011. Kerncijfers verslavingszorg. National Information System on Alcohol and Drugs (LADIS), Stichting Informatie Voorziening Zorg (IVZ). http://www.sivz.nl/ivz-verslavingszorg/127-kerncijfers-verslavingszorg-2010.
67. Parsons J.T., Grov C., Kelly B.C. Club drug use and dependence among young adults recruited through time-space sampling. Public Health Rep. 2009, 124:246-254.
68. Pedraza C., Garciá F.B., Navarro J.F. Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int. J. Neuropsychopharmacol. 2009, 12:1165-1177.
69. Pennings E.J.M., Opperhuizen A., van Amsterdam J.G.C. Risk assessment of khat use. Regul. Toxicol. Pharmacol. 2008, 52:199-207.
70. Perez E., Chu J., Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann. Emerg. Med. 2006, 48:219-220.
71. Rasmussen L.S., Johnson T., Kuipers H.M., Kristensen D., Siersma V.D., Vila P., Jolles J., Papaioannou A., Abildstrom H., Silverstein J.H., Bonal J.A., Raeder J., Nielsen I.K., Korttila K., Munoz L., Dodds C., Hanning C.D., Moller J.T. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol. Scand. 2003, 47:260-266.
72. Schwartz R.H., Milteer R., LeBeau M.A. Drug-facilitated sexual assault ('date rape'). South. Med. J. 2000, 93:558-561.
73. Scott-Ham M., Burton F.C. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J. Clin. Forensic Med. 2005, 12:175-186.
74. Sircar R., Basak A., Sircar D., Wu L.C. Effects of gamma-hydroxybutyric acid on spatial learning and memory in adolescent and adult female rats. Pharmacol. Biochem. Behav. 2010, 96:187-193.
75. Sircar R., Wu L.C., Reddy K., Sircar D., Basak A.K. GHB-induced cognitive deficits during adolescence and the role of NMDA receptor. Curr. Neuropharmacol. 2011, 9:240-243.
76. Sircar R., Basak A. Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-d-aspartate receptor and impairs spatial learning. Pharmacol. Biochem. Behav. 2004, 79:701-708.
77. Smith K.M. Drugs used in acquaintance rape. J. Am. Pharm. Assoc. (Wash.) 1999, 39:519-525.
78. Smith K.M., Larive L.L., Romanelli Fr. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am. J. Health Syst. Pharm. 2002, 59:1067-1076.
79. Snead O.C., Gibson K.M. Gamma-hydroxybutyric acid. N. Engl. J. Med. 2005, 352:2721-2732.
80. Sporer K.A., Chin R.L., Dyer J.E., Lamb R. Gamma-hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann. Emerg. Med. 2003, 42:3-8.
81. Stolte, E., 2009. GHB. Consumer Safety Foundation (Stichting Consument en Veiligheid). http://www.veiligheid.nl.
82. Sumnall H.R., Woolfall K., Edwards S., Cole J.C., Beynon C.M. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008, 92:286-290.
83. van Amsterdam J.G.C., Best W., Opperhuizen A., de Wolff F.A. Evaluation of a procedure to assess the adverse effects of illicit drugs. Regul. Toxicol. Pharmacol. 2004, 39:1-4.
84. van Amsterdam J.G.C., Opperhuizen A., van den Brink W. Harm potential of magic mushroom use: a review. Regul. Toxicol. Pharmacol. 2011, 59:423-429.
85. van der Poel A., Doekhie J., Verdurmen J., Wouters M., van Laar M. Feestmeter 2008-2009: uitgaan en middelengebruik onder bezoekers van party's en clubs 2010, Trimbos-instituut/Bonger Instituut, Utrecht/Amsterdam.
86. van Hees, W., 2010. GBL, cleaning agent or risk? (GBL, schoonmaakmiddel of risico?). Information about GHB to CAM by the National Customs Office.
87. van Laar M., Cruts A.A., van Ooyen-Houben M.M., Meyr R.F., Croes E., Brunt T., Ketelaars A. Netherlands national drug monitor; NDM annual report 2010 2011, Trimbos Institute, Utrecht, The Netherlands.
88. van Noorden M.S., van Dongen L.C.A.M., Zitman F.G., Vergouwen T.A.C.M. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen. Hosp. Psychiatry 2009, 31:394-396.
89. van Rij C.M., Wilhelm A.J., van Loenen A.C. Herkenning en behandeling van hydroxyboterzuurintoxicaties. Ned. Tijdschr. Geneeskd. 2004, 148:844-846.
90. van Rooij A.J., Schoenmakers T.M., van de Mheen D. Nationaal Prevalentie Onderzoek Middelengebruik 2009: kerncijfers 2009 2011, IVO, Rotterdam.
91. Van Sassenbroek D.K., Calle P.A., Rousseau F.M., Verstraete A.G., Belpaire F.M., Monsieurs K.G., Haentjes R., Allonsius J., van Brantegem J., Haenen W., van Buylaert W.A. Medical problems related to recreational drug use at nocturnal dance parties. Eur. J. Emerg. Med. 2003, 10:302-308.
92. Varela M., Nogue S., Oros M., Miro O. Gamma hydroxybutirate use for sexual assault. Emerg. Med. J. 2004, 21:255-256.
93. Veerman S.R.T., Dijkstra H.N., Liefting-Kluft I. Levensbedreigende onthoudingsverschijnselen door gammahydroxyboterzuur. Tijdschr. Psychiatrie 2010, 52:411-416.
94. Veerman S.R.T., Dijkstra H.N., Liefting-Kluft I. Life threatening symptoms of withdrawal of gamma-hydroxybutyrate. [Levensbedreigende onthoudingsverschijnselen door gammahydroxyboterzuur]. Tijdschr. Psychiatr. 2010, 52:411-416.
95. Verstraete A.G. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther. Drug Monit. 2004, 26:200-205.
96. Vijlbrief, M. and de Bruin, N., 2011. Information about GHB to CAM by the National Police Force, Unit South, Expert Centre Synthetic Drugs and Precursors.
97. Vogels, N. and Croes, E., 2011. Monitor Drugs Incident: factsheet 2010. Utrecht: Trimbos-instituut. http://www.trimbos.nl.
98. Vree T.B., Baars A.M., van der Kleijn E. Capaciteits-gelimiteerde eliminatie van 4-hydroxybutyrate, ethanol envinylbital. Pharmac. Weekbl. 1975, 110:1257-1262.
99. Wang Y.G., Swick T.J., Carter L.P., Thorpy M.J., Benowitz N.L. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J. Clin. Sleep Med. 2009, 15:365-371.
100. Ward D., Morgenthaler J., Fowkes S. GHB - The natural mood enhancer 1998, Smart Publications, Petaluma.
101. WHO, 2000. WHO (World Health Organization). Notification to the Secretary-General of the United Nations by the Director-General of the World Health Organization. 4 October 2000.
102. Williams S.R. Gamma-hydroxybutyric acid poisoning. West. J. Med. 1998, 168:187-188.
103. Wolf M. GHB and Analogs: High-risk Club Drugs 2007, The Rosen Publishing group, New York.
104. Zvosec D.L., Smith S.W., McCutcheon J.R., Spillane J., Hall B.J., Peacock E.A. Adverse events, including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. 2001, 344:87-94.
105. Zvosec D.L., Smith S.W., Porrata T., Strobl A.Q., Dyer J.E. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am. J. Emerg. Med. 2011, 29:319-332.